Furmonertinib Mesilate Tablets

DRUG2 trials

Sponsors

First Affiliated Hospital of Zhejiang University, Allist Pharmaceuticals, Inc.

Conditions

NSCLC Patients With Brain MetastasisNon Small Cell Lung Cancer

Phase 2

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

First Affiliated Hospital of Zhejiang UniversityNon Small Cell Lung Cancer

Start: 2022-04-15End: 2025-08-31Target: 30Updated: 2023-04-14

Phase 3

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

RecruitingNCT06970639

Allist Pharmaceuticals, Inc.NSCLC Patients With Brain Metastasis

Start: 2024-09-26End: 2029-09-01Target: 380Updated: 2026-02-12